CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point

English version České info

Cell cycle progression, including genome duplication, is orchestrated by cyclin-dependent kinases (CDKs). CDK activation depends on phosphorylation of their T-loop by a CDK–activating kinase (CAK). In animals, the only known CAK for CDK2 and CDK1 is cyclin H-CDK7, which is constitutively active. Therefore, the critical activation step is dephosphorylation of inhibitory sites by Cdc25 phosphatases rather than unrestricted T-loop phosphorylation. Homologous CDK4 and CDK6 bound to cyclins D are master integrators of mitogenic/oncogenic signaling cascades by initiating the inactivation of the central oncosuppressor pRb and cell cycle commitment at the restriction point. Unlike the situation in CDK1 and CDK2 cyclin complexes, and in contrast to the weak but constitutive T177 phosphorylation of CDK6, we have identified the T-loop phosphorylation at T172 as the highly regulated step determining CDK4 activity. Whether both CDK4 and CDK6 phosphorylations are catalyzed by CDK7 remains unclear. To answer this question, we took a chemical-genetics approach by using analogue-sensitive CDK7(as/as) mutant HCT116 cells, in which CDK7 can be specifically inhibited by bulky adenine analogs. Intriguingly, CDK7 inhibition prevented activating phosphorylations of CDK4/6, but for CDK4 this was at least partly dependent on its binding to p21^cip1. In response to CDK7 inhibition, p21-binding to CDK4 increased concomitantly with disappearance of the most abundant phosphorylation of p21, which we localized at S130 and found to be catalyzed by both CDK4 and CDK2. The S130A mutation of p21 prevented the activating CDK4 phosphorylation, and inhibition of CDK4/6 and CDK2 impaired phosphorylations of both p21 and p21-bound CDK4. Therefore, specific CDK7 inhibition revealed the following: a crucial but partly indirect CDK7 involvement in phosphorylation/activation of CDK4 and CDK6; existence of CDK4-activating kinase(s) other than CDK7; and novel CDK7-dependent positive feedbacks mediated by p21 phosphorylation by CDK4 and CDK2 to sustain CDK4 activation, pRb inactivation, and restriction point passage.

Vyšlo v časopise: CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point. PLoS Genet 9(5): e32767. doi:10.1371/journal.pgen.1003546
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003546

Souhrn

Zdroje

1. SherrCJ (1995) D-type cyclins. Trends Biochem Sci 20: 187–190.

2. BartekJ, BartkovaJ, LukasJ (1996) The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 8: 805–814.

3. BockstaeleL, CoulonvalK, KookenH, PaternotS, RogerPP (2006) Regulation of CDK4. Cell Division 1: 25.

4. LundbergAS, WeinbergRA (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753–761.

5. YaoG, LeeTJ, MoriS, NevinsJR, YouL (2008) A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol 10: 476–482.

6. SherrCJ, RobertsJM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501–1512.

7. PeiXH, XiongY (2005) Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 24: 2787–2795.

8. AbbasT, DuttaA (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400–414.

9. HengstL, GopfertU, LashuelHA, ReedSI (1998) Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). Genes Dev 12: 3882–3888.

10. LaBaerJ, GarrettMD, StevensonLF, SlingerlandJM, SandhuC, et al. (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847–862.

11. BlainSW, MontalvoE, MassagueJ (1997) Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem 272: 25863–25872.

12. SheaffRJ, GroudineM, GordonM, RobertsJM, ClurmanBE (1997) Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11: 1464–1478.

13. GrimmlerM, WangY, MundT, CilensekZ, KeidelEM, et al. (2007) Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128: 269–280.

14. ChuI, SunJ, ArnaoutA, KahnH, HannaW, et al. (2007) p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128: 281–294.

15. RayA, JamesMK, LarochelleS, FisherRP, BlainSW (2009) p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol Cell Biol 29: 986–999.

16. OuL, WaddellMB, KriwackiRW (2012) Mechanism of cell cycle entry mediated by the intrinsically disordered protein p27(Kip1). ACS Chem Biol 7: 678–682.

17. JakelH, PeschelI, KunzeC, WeinlC, HengstL (2012) Regulation of p27 (Kip1) by mitogen-induced tyrosine phosphorylation. Cell Cycle 11: 1910–1917.

18. SherrCJ, McCormickF (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103–112.

19. MusgroveEA, CaldonCE, BarracloughJ, StoneA, SutherlandRL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11: 558–572.

20. KozarK, CiemerychMA, RebelVI, ShigematsuH, ZagozdzonA, et al. (2004) Mouse development and cell proliferation in the absence of D-cyclins. Cell 118: 477–491.

21. Miliani de MarvalPL, MaciasE, RounbehlerR, SicinskiP, KiyokawaH, et al. (2004) Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol 24: 7538–7547.

22. Rodriguez-PueblaML, Miliani de MarvalPL, LaCavaM, MoonsDS, KiyokawaH, et al. (2002) Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol 161: 405–411.

23. MalumbresM, BarbacidM (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153–166.

24. PuyolM, MartinA, DubusP, MuleroF, PizcuetaP, et al. (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18: 63–73.

25. ChoiYJ, LiX, HydbringP, SandaT, StefanoJ, et al. (2012) The requirement for cyclin D function in tumor maintenance. Cancer Cell 22: 438–451.

26. WangL, WangJ, BlaserBW, DucheminAM, KusewittDF, et al. (2007) Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 110: 2075–2083.

27. BaughnLB, Di LibertoM, WuK, ToogoodPL, LouieT, et al. (2006) A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 66: 7661–7667.

28. MichaudK, SolomonDA, OermannE, KimJS, ZhongWZ, et al. (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70: 3228–3238.

29. RobertsPJ, BisiJE, StrumJC, CombestAJ, DarrDB, et al. (2012) Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. J Natl Cancer Inst 104: 476–487.

30. KatoJY, MatsuokaM, StromDK, SherrCJ (1994) Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol 14: 2713–2721.

31. BockstaeleL, KookenH, LibertF, PaternotS, DumontJE, et al. (2006) Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK “inhibitors”. Mol Cell Biol 26: 5070–5085.

32. KaldisP, RussoAA, ChouHS, PavletichNP, SolomonMJ (1998) Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 9: 2545–2560.

33. BockstaeleL, BisteauX, PaternotS, RogerPP (2009) Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol Cell Biol 29: 4188–4200.

34. HwangHC, ClurmanBE (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776–2786.

35. PaternotS, BockstaeleL, BisteauX, KookenH, CoulonvalK, et al. (2010) Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 9: 689–699.

36. RochaAS, PaternotS, CoulonvalK, DumontJE, SoaresP, et al. (2008) Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell 19: 4814–4825.

37. PaternotS, RogerPP (2009) Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Cancer Res 69: 4577–4581.

38. BlancquaertS, WangL, PaternotS, CoulonvalK, DumontJE, et al. (2010) Cyclic AMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Mol Endocrinol 24: 1453–1468.

39. PaternotS, CoulonvalK, DumontJE, RogerPP (2003) Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells. J Biol Chem 278: 26533–26540.

40. CoulonvalK, BockstaeleL, PaternotS, RogerPP (2003) Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis. J Biol Chem 278: 52052–52060.

41. CoulonvalK, KookenH, RogerPP (2011) Coupling of T161 and T14 phosphorylations protects cyclin B-CDK1 from premature activation. Mol Biol Cell 22: 3971–3985.

42. FisherRP, MorganDO (1994) A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78: 713–724.

43. FisherRP, JinP, ChamberlinHM, MorganDO (1995) Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell 83: 47–57.

44. KaldisP (1999) The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol Life Sci 55: 284–296.

45. TassanJP, SchultzSJ, BartekJ, NiggEA (1994) Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol 127: 467–478.

46. MatsuokaM, KatoJY, FisherRP, MorganDO, SherrCJ (1994) Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol 14: 7265–7275.

47. PaternotS, DumontJE, RogerPP (2006) Differential utilization of cyclin D1 and cyclin D3 in the distinct mitogenic stimulations of human thyrocytes by growth factors and TSH. Mol Endocrinol 20: 3279–3292.

48. KatoJY, MatsuokaM, PolyakK, MassagueJ, SherrCJ (1994) Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 79: 487–496.

49. LarochelleS, BatlinerJ, GambleMJ, BarbozaNM, KraybillBC, et al. (2006) Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol 13: 55–62.

50. FisherRP (2005) Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118: 5171–5180.

51. GarrettS, BartonWA, KnightsR, JinP, MorganDO, et al. (2001) Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol Cell Biol 21: 88–99.

52. LolliG, JohnsonLN (2007) Recognition of Cdk2 by Cdk7. Proteins 67: 1048–1059.

53. LarochelleS, MerrickKA, TerretME, WohlboldL, BarbozaNM, et al. (2007) Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 25: 839–850.

54. UmedaM, ShimotohnoA, YamaguchiM (2005) Control of cell division and transcription by cyclin-dependent kinase-activating kinases in plants. Plant Cell Physiol 46: 1437–1442.

55. KaldisP, SolomonMJ (2000) Analysis of CAK activities from human cells. Eur J Biochem 267: 4213–4221.

56. HarperJW, ElledgeSJ (1998) The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev 12: 285–289.

57. MerrickKA, FisherRP (2012) Why minimal is not optimal: Driving the mammalian cell cycle-and drug discovery-with a physiologic CDK control network. Cell Cycle 11: 2600–2605.

58. ChengM, OlivierP, DiehlJA, FeroM, RousselMF, et al. (1999) The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571–1583.

59. BaguiTK, MohapatraS, HauraE, PledgerWJ (2003) P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes. Mol Cell Biol 23: 7285–7290.

60. SugimotoM, MartinN, WilksDP, TamaiK, HuotTJ, et al. (2002) Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1). Oncogene 21: 8067–8074.

61. ZhuH, NieL, MakiCG (2005) Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem 280: 29282–29288.

62. BornsteinG, BloomJ, Sitry-ShevahD, NakayamaK, PaganoM, et al. (2003) Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 278: 25752–25757.

63. BashirT, DorrelloNV, AmadorV, GuardavaccaroD, PaganoM (2004) Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 428: 190–193.

64. ChenJ, SahaP, KornbluthS, DynlachtBD, DuttaA (1996) Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol 16: 4673–4682.

65. RossigL, BadorffC, HolzmannY, ZeiherAM, DimmelerS (2002) Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 277: 9684–9689.

66. BachS, KnockaertM, ReinhardtJ, LozachO, SchmittS, et al. (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280: 31208–31219.

67. Wesierska-GadekJ, BorzaA, KominaO, MaurerM (2009) Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential. Acta Biochim Pol 56: 495–501.

68. BettayebK, OumataN, EchalierA, FerandinY, EndicottJA, et al. (2008) CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 27: 5797–5807.

69. ChenJ, LarochelleS, LiX, SuterB (2003) Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature 424: 228–232.

70. ToogoodPL, HarveyPJ, RepineJT, SheehanDJ, VanderWelSN, et al. (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 48: 2388–2406.

71. WangY, FisherJC, MathewR, OuL, OtienoS, et al. (2011) Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21. Nat Chem Biol 7: 214–221.

72. Merzel SchachterM, MerrickKA, LarochelleS, HirschiA, ZhangC, et al. (2013) A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression. Mol Cell 50: 250–260.

73. MerrickKA, LarochelleS, ZhangC, AllenJJ, ShokatKM, et al. (2008) Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol Cell 32: 662–672.

74. GanuzaM, Saiz-LaderaC, CanameroM, GomezG, SchneiderR, et al. (2012) Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J 31: 2498–2510.

75. TakakiT, EchalierA, BrownNR, HuntT, EndicottJA, et al. (2009) The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci U S A 106: 4171–4176.

76. DarbonJM, DevaultA, TaviauxS, FesquetD, MartinezAM, et al. (1994) Cloning, expression and subcellular localization of the human homolog of p40MO15 catalytic subunit of cdk-activating kinase. Oncogene 9: 3127–3138.

77. MullerD, BouchardC, RudolphB, SteinerP, StuckmannI, et al. (1997) Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 15: 2561–2576.

78. KamuraT, HaraT, KotoshibaS, YadaM, IshidaN, et al. (2003) Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A 100: 10231–10236.

79. JarviluomaA, ChildES, SarekG, SirimongkolkasemP, PetersG, et al. (2006) Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 26: 2430–2440.

80. ZhangH, HannonGJ, BeachD (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8: 1750–1758.

81. LinJ, ReichnerC, WuX, LevineAJ (1996) Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol 16: 1786–1793.

82. ZhanJ, EastonJB, HuangS, MishraA, XiaoL, et al. (2007) Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol 27: 3530–3541.

83. ThronCD (1999) Mathematical analysis of binary activation of a cell cycle kinase which down-regulates its own inhibitor. Biophys Chem 79: 95–106.

84. ThronCD (1997) Bistable biochemical switching and the control of the events of the cell cycle. Oncogene 15: 317–325.

85. PaternotS, ArsenijevicT, CoulonvalK, BockstaeleL, DumontJE, et al. (2006) Distinct Specificities of pRb Phosphorylation by CDK4 Activated by Cyclin D1 or Cyclin D3: Differential Involvement in the Distinct Mitogenic Modes of Thyroid Epithelial Cells. Cell Cycle 5: 61–70.

86. HwangCY, LeeC, KwonKS (2009) Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol 29: 3379–3389.

87. KnudsenES, WangJY (2010) Targeting the RB-pathway in cancer therapy. Clin Cancer Res 16: 1094–1099.

88. KwongLN, CostelloJC, LiuH, JiangS, HelmsTL, et al. (2012) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18: 1503–1510.

89. CoulonvalK, BockstaeleL, PaternotS, DumontJE, RogerPP (2003) The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFbeta, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis. Exp Cell Res 291: 135–149.

90. ClurmanBE, SheaffRJ, ThressK, GroudineM, RobertsJM (1996) Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10: 1979–1990.

91. LinJ, JinnoS, OkayamaH (2001) Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell's proliferation competence. Oncogene 20: 2000–2009.

92. LarochelleS, ChenJ, KnightsR, PandurJ, MorcilloP, et al. (2001) T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J 20: 3749–3759.

93. Glover-CutterK, LarochelleS, EricksonB, ZhangC, ShokatK, et al. (2009) TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol 29: 5455–5464.

94. BettayebK, BaunbaekD, DelehouzeC, LoaecN, HoleAJ, et al. (2010) CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer 1: 369–380.